Investor Presentaiton

Investor presentation Full year 2018 Slide 54 Stable global insulin market growth and Novo Nordisk sustains global volume market share leadership Global insulin market Global modern and new-generation insulin volume market shares Device penetration Modern insulin penetration¹ tMU CAGR volume¹: 4.5% Penetration 500 CAGR value¹: 13.7% 100% 60% 400 50% 80% 40% 300 60% MI and NGI² 30% 200 Market value³: bDKK 2,647 - 40% 20% 100 Human insulin 20% 10% Market value³: bDKK 283 0 0% 0% Nov 2013 Nov 2018 1 CAGR for 5-year period; 2 MI: Modern insulin; NGI: New-generation insulin 3 Annual gross value of total insulin class Note: Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA monthly MAT Nov, 2018 volume and value figures changing diabetes - Novo Nordisk Sanofi Eli Lilly Nov 2013 Note: Data is sensitive to changes in IQVIA data collection and reporting methodology, does not add up to 100% as only selected pharmaceutical companies are included Source: IQVIA monthly MAT Nov, 2018 volume figures 45% 32% 21% Nov 2018 novo nordisk

View entire presentation